ICON recently increased its expectations for earnings this year. The 2008 earnings per diluted share rose from $1.27 to $1.29, up from $1.23 to $1.26.
ICON CEO Peter Gray had this to say about the increase in earnings:
“For 2008 overall, we expect to report revenues in the range of $862 to $865 million, which is a modest reduction in previous guidance reflecting the impact of currency volatility over the last six months.”
This comes at a time when most CROs are lowing their profit and revenue outlooks. For more, read the article at Clinical Trials Today.
Search This Blog
Blog Archive
-
▼
2009
(141)
-
▼
January
(20)
- Drug CROs: Good Medicine for Investors
- Quintiles partners with India’s Apollo Hospitals G...
- Kendle expands in India
- Free Webinar: The Benefits of Establishing a Gover...
- Read the January Partnerships with CROs LinkedIn R...
- Project Management in the Life Sciences: Results f...
- Indigo BioSystems Successfully Tests First Globall...
- Problems in Patient Recruitment in Outsourced Clin...
- ICON annouced as the Clinical Research Company of ...
- Icon increased 2008 earnings
- IRBs are Overloaded with Adverse Events
- South Africa seeing less funding for clinical trials
- FDA Limits Interest in Clinical Trials
- India Expected to Draw More Clinical Trials by 2012
- Insurance and clinical trials
- RNCOS: India Most Economical Destination for Globa...
- Merck and PPD Partner in Outsourcing Deal
- Brazil is critical base for PPD's CROs efforts
- India Offers More Education for Clinical Research
- Ethical Guidelines in India
-
▼
January
(20)
No comments:
Post a Comment